DARE - Daré gets Gates Foundation grant to develop Hydrogel tech for use in vaginal health

• Daré Bioscience ( NASDAQ: DARE ) said it received a grant of ~$585K from the Bill & Melinda Gates Foundation to support development of a vaginal thermosetting gel formulation for delivery of live biotherapeutics which can be reconstituted at the point of care.
• If successful, the formulation could be carried forward for further development as a delivery vehicle with potential to enhance the availability of new therapies for vaginal health worldwide, including in countries with varying climatic conditions and/or where extended storage may be required, the company added.
• "This grant will enable us to investigate the use of a novel hydrogel technology to deliver live biotherapeutics to address this challenge that affects women everywhere," said Daré's Chief Scientific Officer David Friend.
• Daré noted that its FDA approved product Xaciato (clindamycin phosphate) vaginal gel 2% to treat bacterial vaginosis uses hydrogel technology.

For further details see: